1. Home
  2. RNAZ vs OP Comparison

RNAZ vs OP Comparison

Compare RNAZ & OP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNAZ
  • OP
  • Stock Information
  • Founded
  • RNAZ 2016
  • OP 2021
  • Country
  • RNAZ United States
  • OP Greece
  • Employees
  • RNAZ N/A
  • OP N/A
  • Industry
  • RNAZ Biotechnology: Pharmaceutical Preparations
  • OP
  • Sector
  • RNAZ Health Care
  • OP
  • Exchange
  • RNAZ Nasdaq
  • OP Nasdaq
  • Market Cap
  • RNAZ 8.7M
  • OP 8.6M
  • IPO Year
  • RNAZ 2021
  • OP N/A
  • Fundamental
  • Price
  • RNAZ $14.80
  • OP $1.35
  • Analyst Decision
  • RNAZ Strong Buy
  • OP
  • Analyst Count
  • RNAZ 1
  • OP 0
  • Target Price
  • RNAZ $280.00
  • OP N/A
  • AVG Volume (30 Days)
  • RNAZ 387.0K
  • OP 260.2K
  • Earning Date
  • RNAZ 11-13-2025
  • OP 08-08-2025
  • Dividend Yield
  • RNAZ N/A
  • OP N/A
  • EPS Growth
  • RNAZ N/A
  • OP N/A
  • EPS
  • RNAZ N/A
  • OP N/A
  • Revenue
  • RNAZ N/A
  • OP $19,435,000.00
  • Revenue This Year
  • RNAZ N/A
  • OP N/A
  • Revenue Next Year
  • RNAZ N/A
  • OP N/A
  • P/E Ratio
  • RNAZ N/A
  • OP N/A
  • Revenue Growth
  • RNAZ N/A
  • OP N/A
  • 52 Week Low
  • RNAZ $6.15
  • OP $1.07
  • 52 Week High
  • RNAZ $739.20
  • OP $79.25
  • Technical
  • Relative Strength Index (RSI)
  • RNAZ 84.37
  • OP 57.48
  • Support Level
  • RNAZ $10.32
  • OP $1.22
  • Resistance Level
  • RNAZ $12.28
  • OP $1.33
  • Average True Range (ATR)
  • RNAZ 0.87
  • OP 0.07
  • MACD
  • RNAZ 0.57
  • OP -0.02
  • Stochastic Oscillator
  • RNAZ 91.34
  • OP 24.75

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

About OP OceanPal Inc.

OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.

Share on Social Networks: